MR Angiography Follow-Up 5 Years after Coiling: Frequency of New Aneurysms and Enlargement of Untreated Aneurysms

BACKGROUND AND PURPOSE: Patients with intracranial aneurysms are at risk for future development of new aneurysms and growth of additional untreated aneurysms. Because in previous long-term studies duration of follow-up varied widely, the time interval after which screening could be effective remains largely unknown. The purpose of this study was to assess the incidence of de novo aneurysm formation and the growth of additional untreated aneurysms in patients with coiled aneurysms followed up with MR angiography (MRA) after a fixed period of 5 years.

MATERIALS AND METHODS: In 65 patients with coiled intracranial aneurysms, high-resolution 3T MRA was performed 5.1 ± 0.2 years after coiling. MRA follow-up imaging was compared with MRA or CT angiography at the time of coiling. Additional aneurysms detected at MRA follow-up were classified as unchanged, grown, de novo, or incomparable with previous imaging.

RESULTS: In 13 of 65 patients (20%), 24 additional aneurysms were found. Four aneurysms were incomparable with previous imaging and 2 of these were clipped. Of the remaining 20 additional aneurysms, 1 was de novo, 1 had grown slightly, and 18 were unchanged. The incidence of de novo aneurysm formation after 5 years was 1.54% (95% confidence interval, 0.01–9.0%). For additional aneurysms known at the time of initial coiling and for the 1 de novo aneurysm, no treatment was indicated.

CONCLUSIONS: MRA screening 5 years after coiling for detection of de novo aneurysms and growth of additional untreated aneurysms has a low yield in terms of finding aneurysms that need to be treated.
MR Imaging and MRA Follow-Up Protocol

MR imaging examinations were performed on a 3T system (Intera R10; Philips Medical Systems, Best, the Netherlands) by using the sensitivity encoding (SENSE) phased array head coil (MRI Devices, Gainesville, Fla). MR imaging protocol included axial T2-weighted fast spin-echo and multiple overlapping thin-slab acquisition 3D time-of-flight (MOTSA 3D-TOF) MRA sequences. Imaging parameters for the T2-weighted fast spin-echo sequence were the following: TR/TE, 3394/80 ms; 400 × 400 matrix (reconstructed to 512 × 512); 230-mm FOV; 70% rectangular FOV; 5-mm-thick sections with a 0.5-mm gap. The volume of the MOTSA 3D-TOF MRA was localized on a sagittal 2D phase-contrast scout image. A presaturation band was applied above the imaging volume to saturate incoming venous blood. For the MOTSA 3D-TOF MR image, the parameters were the following: 3D fast-field echo T1-weighted sequence; TR/TE, 21/4 ms; flip angle, 20°; 512 × 512 matrix (reconstructed to 1024 × 1024); 200-mm FOV; 85% rectangular FOV; 1.0-mm-thick sections, interpolated to 0.5 mm; 160 sections acquired in 8 chunks. The measured voxel size of the MOTSA 3D-TOF MR image was 0.39 × 0.61 × 1 mm, and the reconstructed voxel size was 0.2 × 0.2 × 0.5 mm. Acquisition time of the high-resolution MOTSA 3D TOF sequence was reduced by SENSE parallel imaging. Total MR imaging examination time was 20 minutes. The usefulness of this 3T MRA protocol in the follow-up of coiled intracranial aneurysms was validated in a previous study.3

MR Imaging and MRA Evaluation

MR and MRA imaging (axial source images, maximum intensity projections, and volume rendered images) were evaluated and compared with previous imaging studies in 2 institutions by 2 experienced neuroradiologists (M.E.S. and C.B.L.M.M. or B.K.V. and G.A.P.d.K.) independently. Discrepancies were resolved in consensus.

Location and size of additional aneurysms were recorded and compared with MRA or CT angiography (CTA) at the time of coiling. Subsequently, these aneurysms were classified as unchanged, grown, de novo, or incomparable with previous imaging.

Clinical implication in terms of treatment advice and change of follow-up imaging policy of these 5-year-follow-up findings was assessed.

Results

Between January 1, 1995, and December 31, 2002, 661 aneurysms in 612 patients were coiled in the 3 participating centers (Tilburg, 483 [76%]; Utrecht, 105 [16%]; and Amsterdam, 24 [8%]). Of 612 patients, 457 with 497 aneurysms had 6-month follow-up angiography, and 316 aneurysms in 297 patients were adequately occluded at this first angiographic follow-up (Fig 1). Of 297 eligible patients with 316 aneurysms, 84 were excluded for the following reasons: dependent functional state in 5, age older than 70 years in 39, 3T MR imaging contraindication in 27 (clipped additional aneurysms in 18, claustrophobia in 4, and a pacemaker in 5), unrelated death in 13 (cancer in 6, cardiovascular disease in 3, old age in 1, and unknown but unlikely subarachnoid hemorrhage [SAH] in 3). Seventy-three patients could not be traced, but many of these patients had previous clinical or angiographic follow-up beyond the 6-month interval. The remaining 140 patients were invited to participate in the study, of whom 36 declined. Thus, 104 patients (Tilburg, 74 [71%]; Utrecht, 25 [24%]; and Amsterdam, 5 [5%]) with 111 aneurysms were followed up with MRA.

Of the total 104 patients, 39 patients with 46 aneurysms had a follow-up interval of >5 years. Sixty-five patients with 65 coiled aneurysms had a consistent MRA follow-up of 5.1 ± 0.2 years after coiling. These patients are the subject of this study. There were 46 women and 19 men with a mean age of 54 years (39–70 years). Of 65 coiled aneurysms, 54 were ruptured and 11, unruptured.

In 13 of 65 patients (20.0%), 24 additional aneurysms were found. Characteristics of patients with additional aneurysms on 5-year MRA follow-up are displayed in the Table. Eight
patients had 1 additional aneurysm, 2 patients had 2, and 3 patients had ≥3 additional aneurysms.

In 3 of 24 additional aneurysms, no previous imaging was available, and these aneurysms were classified as incomparable. In another 1-mm choroidal artery aneurysm, the projections of the initial carotid artery angiogram did not allow verification of its presence or absence, and this aneurysm was also classified as incomparable. The remaining 20 additional aneurysms could be compared with previous imaging: 18 of 20 were classified as unchanged; 1, as having grown; and 1, as de novo. The 18 unchanged additional aneurysms were present in 11 patients. Sizes ranged from 1 to 6 mm; an example is provided in Fig 2.

The only additional aneurysm that had grown was a pericallosal artery aneurysm in a patient with 5 additional aneurysms that increased from 1.5 to 2.5 mm in 5 years (Fig 3). The only definite de novo aneurysm was a 3-mm middle cerebral artery aneurysm (Fig 4).

The 4 additional aneurysms that could not be compared with previous imaging were present in 2 patients. One patient had the 1-mm choroidal artery aneurysm that could not be verified on the available projections of the carotid angiogram. The other patient had 4 additional aneurysms, 3 of which were not imaged before. The location and size of these 3 aneurysms were the following: 1 on the superior cerebellar artery (3 mm) and 2 on the left middle cerebral artery (3 and 6 mm) (Fig 5).
Cerebral artery aneurysms were clipped. Of 24 additional aneurysms, 2 left middle cerebral aneurysms (5%) had enlarged 1 mm after 5 years. In the cited CTA follow-up study, in the first 5 years after SAH, 4 of 18 aneurysms (22%) had enlarged with a rate of 0.12–1.3 mm per year.

These figures are only valid for patients who survived at least 5 years after treatment of an aneurysm without recurrent SAH. The risk of recurrent SAH after treatment was assessed in a follow-up study after clipping of ruptured aneurysms. In this study the incidence rate of recurrent SAH in the first 10 years after clipping was 286 per 100,000, whereas in the general population, this figure is 9–10 per 100,000. However, during the first 33 months, no recurrent SAH was observed from de novo or regrowth aneurysms. In another study, short-term (1–2 years) CTA follow-up of small aneurysms detected at screening in patients with a history of SAH or with familial aneurysms did not eliminate the risk of recurrent SAH: Two of 93 patients had a recurrent SAH, 1 from the clipped aneurysm and 1 from a new dissecting aneurysm. In that study, in 3 of 93 patients, the small aneurysm detected at screening had enlarged slightly.

Combining these data suggests that the risk of de novo aneurysm formation and significant enlargement of additional untreated aneurysms is low, with subsequently an extremely low risk of SAH from these aneurysms. This low risk seems particularly true for the first 5 years and probably also for the first 10 years. Therefore, screening all patients within the first 5 years after aneurysm treatment does not seem beneficial, both in terms of preventing SAH and for detection of aneurysms that need treatment. From the patient’s perspective, follow-up screening may be two-sided: In patients with fear of a recurrence, it may increase the quality of life when no such recurrence is found, but screening may have a negative impact when aneurysms are detected that remain untreated.

A limitation of our study is the small sample size of 65 patients. However, the consistent MRA follow-up period of 5 years makes this group rather unique for comparison of angiographic data. Another limitation of our study is that we did not search for risk factors. In view of the low event rate, large patient groups are needed to identify risk factors. Such studies have been performed and showed that risk factors for aneurysm development and enlargement of existing aneurysms are the following: presence of multiple aneurysms, a history of hypertension, and current smoking. Other risk factors are a positive family history and female gender. These risk factors, except of course the presence of multiple aneurysms, are similar to those for intracranial aneurysms and SAH in general.

Although current available data suggest a low yield of MRA screening at 5 years for patients with treated aneurysms, this may be different for subgroups of patients with increased risk, such as young patients with multiple aneurysms, patients with a positive family history, or patients with proved growth of additional aneurysms. Currently, not enough data are available and larger follow-up studies, preferably with fixed follow-up intervals, are needed to identify subgroups that might benefit from screening at 5 years.

**Conclusions**

MRA screening 5 years after clipping for the detection of de novo aneurysms and for growth of additional untreated aneu-
Aneurysms has a low yield in terms of finding aneurysms that need to be treated. After 5-year follow-up MRA in this group of 65 patients with coiled intracranial aneurysms, we found 1 small de novo aneurysm and 1 small additional aneurysm that showed a minimal growth. Treatment for these aneurysms was not indicated.

References
1. van Rooij WJ, Sprengers ME, de Gast AN, et al. 3D rotational angiography: the new gold standard in the detection of additional intracranial aneurysms. AJNR Am J Neuroradiol 2008;29:976–79.
2. Wermer MJ, van der Schaaf IC, Velthuis BK, et al, for the ASTRA Study Group. Follow-up screening after subarachnoid haemorrhage: frequency and determinants of new aneurysms and enlargement of existing aneurysms. Brain 2005;128(pt 10):2421–29. Epub 2005 Jul 6.
3. van der Schaaf IC, Velthuis BK, Wermer MJ, et al, for the ASTRA Study Group. New detected aneurysms on follow-up screening in patients with previously clipped intracranial aneurysms: comparison with DSA or CTA at the time of SAH. Stroke 2005;36:1753–58. Epub 2005 Jul 7.
4. Juvela S, Poussa K, Poussa M. Factors affecting formation and growth of intracranial aneurysms: a long-term follow-up study. Stroke 2001;32:485–91.
5. David CA, Vishteh AG, Spetzler RF, et al. Late angiographic follow-up review of surgically treated aneurysms. J Neurosurg 1999;91:396–401.
6. Tsutsumi K, Ueki K, Morita A, et al. Risk of aneurysm recurrence in patients with clipped cerebral aneurysms: results of long-term follow-up angiography. Stroke 2001;32:1191–94.
7. Wermer MJ, van der Schaaf IC, Velthuis BK, et al. Yield of short-term follow-up CT/MR angiography for small aneurysms detected at screening. Stroke 2006;37:414–18.
8. Juvela S, Poussa K, Heiskanen O. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. J Neurosurg 1999;81:174–82.
9. Majoe CB, Sprengers ME, van Rooij WJ, et al. MR angiography at 3T versus digital subtraction angiography in the follow-up of intracranial aneurysms treated with detachable coils. AJNR Am J Neuroradiol 2005;26:1349–56.
10. Sprengers ME, Schaafsma J, van Rooij WJ, et al. Stability of intracranial aneurysms adequately occluded 6 months after coiling: a 3T MR angiography multicenter long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1768–74.
11. Wermer MJ, Greebe P, Algra A, et al. Incidence of recurrent subarachnoid hemorrhage after clipping for ruptured intracranial aneurysms. Stroke 2005;36:2394–99.
12. Wermer MJ, Koffijberg H, van der Schaaf IC, for the ASTRA Study Group. Effectiveness and costs of screening for aneurysms every 5 years after subarachnoid hemorrhage. Neurology 2008;70:2055–62. Epub 2008 Apr 16.
13. Juvela S, Poussa M, Poussa K. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. J Neurosurg 2008;108:1052–60.
14. Rinkel GJ, Dhibouti M, Algra A, van Gijs J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998;29:251–56.
15. Wermer MJ, Buskens E, van der Schaaf IC, et al. Yield of screening for new aneurysms after treatment for subarachnoid hemorrhage. Neurology 2004;62:369–75.